Details for Patent: 8,618,160
Which drugs does patent 8,618,160 protect, and when does it expire?
Patent 8,618,160 protects QBREXZA and is included in one NDA.
This patent has nine patent family members in six countries.
Summary for Patent: 8,618,160
| Title: | Topical glycopyrrolate formulations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Michael Johnston, Robert James Houlden | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Rose U LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/738,168 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,618,160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,618,160: Glycopyrrolate Hyperhidrosis Wipe Claims, Patent Scope, and Competitive LandscapeUS Patent No. 8,618,160 protects a specific topical hyperhidrosis wipe system rather than glycopyrrolate generally. Its core combination requires a glycopyrrolate compound, an approximately 50:50 to 70:30 alcohol-water vehicle, an approximately pH 4.5 buffer at 10-20 mM, packaging in a leakage-resistant pouch, and demonstrated glycopyrrolate degradation of less than 0.5% after three months at 40°C. The patent also covers selected pouch materials, excipients, buffer systems, ethanol concentrations, wipe substrates, and treatment use. The claim set is closely aligned with the product architecture of Qbrexza, the glycopyrronium tosylate topical cloth approved by the FDA for primary axillary hyperhidrosis. The patent does not, on its face, create a monopoly over all glycopyrronium formulations, all hyperhidrosis treatments, or all topical wipes. What does US Patent 8,618,160 protect?The patent protects an individually packaged, chemically stable medicated wipe with defined formulation and packaging parameters.
Claim 1 is the principal composition-and-package claim. Claims 2-8, 10-13 narrow that combination. Claim 9 is a method-of-treatment claim that depends on use of the wipe of claim 1. How broad is independent claim 1?Claim 1 has substantial breadth in the identity of the glycopyrrolate compound, wipe substrate, alcohol, and packaging construction. It is narrower in the formulation and stability requirements. Active ingredient scopeThe phrase "glycopyrrolate compound" is broader than a claim limited expressly to glycopyrronium tosylate. Depending on the specification and claim-construction record, it may encompass glycopyrrolate, glycopyrronium salts, solvates, hydrates, and other pharmaceutically acceptable forms. That breadth is constrained by the requirement that the compound be present in a topical wipe at approximately 0.25% to 6% w/w. A product using a different anticholinergic, such as oxybutynin or sofpironium, would not literally meet this active-ingredient limitation. Vehicle scopeThe alcohol-water ratio is a central limitation. A formulation outside the approximately 50:50 to 70:30 alcohol-water range presents a straightforward noninfringement position if the ratio is measured consistently with the patent specification. Claim 10 narrows the alcohol to ethanol. Claim 1, however, does not expressly limit the alcohol to ethanol. This creates potential coverage for other pharmaceutically acceptable alcohols if the remaining limitations are met. Buffer and pH limitationsClaim 1 requires both:
A formulation with a pH near 4.5 but no buffering capacity, or with a buffer concentration materially outside 10-20 mM, has a potential claim-scope defense. The interpretation of "about" will depend on the specification, prosecution history, and ordinary pharmaceutical formulation practice. The dependent claims identify two buffer systems:
Those alternatives do not limit claim 1 unless a product is being assessed against claims 4 or 5. Stability limitationThe less-than-0.5% degradation requirement is unusually important. It is a performance limitation, not merely an ingredient limitation. A competing product may contain the same active, ethanol, water, and buffer but avoid claim 1 if it cannot be shown to meet the specified accelerated-stability result. The limitation raises evidentiary questions:
These issues can materially affect infringement analysis. What do claims 2 through 13 add?
Claims 6-8 contain drafting complexity. Claim 6 refers to an alcohol-water ratio of approximately 40:60 to 60:40 while also specifying alcohol at approximately 53.7%-57.3% w/w. Claim 7 and claim 8 use a clearer percentage formulation structure. In litigation, the relationship between these limitations could affect claim construction and written-description arguments. What formulations are protected by US 8,618,160?The strongest commercial coverage is directed to a formulation with the following profile:
This profile overlaps materially with Qbrexza, whose active pharmaceutical ingredient is glycopyrronium tosylate and whose dosage form is an individually packaged topical cloth for primary axillary hyperhidrosis (FDA, 2018). The claims do not expressly require a particular dose per cloth, cloth dimensions, total liquid loading, or axillary-only application. Those omissions expand potential coverage, although the product must still satisfy the active concentration, pH, buffer, vehicle, packaging, and stability limitations. When does US Patent 8,618,160 lose exclusivity?The patent has a nominal United States term extending into the late 2029-2030 period based on its priority and filing history. The controlling date is the USPTO patent-term record, including any patent-term adjustment, terminal disclaimer, or other term modification. FDA regulatory exclusivity is separate from patent exclusivity. Qbrexza received FDA approval on June 18, 2018. Its five-year new chemical entity exclusivity period expired in June 2023, subject to the FDA’s regulatory records and any applicable exclusivity adjustments (FDA, 2018; FDA, 2024).
What is the Orange Book status of US 8,618,160?Qbrexza is listed in the FDA Orange Book under its approved active ingredient and dosage form. Orange Book patent listings can include formulation, method-of-use, and other patents identified by the NDA holder. The listing of a patent does not establish that every claim will survive validity review or that every generic product infringes. For an ANDA applicant, a listed patent creates the possibility of:
A Paragraph IV notice can trigger a 45-day period for the NDA holder to file suit. A timely infringement action generally can impose a 30-month stay on ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action (21 U.S.C. § 355; FDA, 2024). Which companies are challenging Qbrexza patent protection?Publicly verifiable competitive risk should be separated into three categories:
A generic competitor would face technical barriers beyond active-ingredient equivalence. These include wipe saturation, content uniformity, pouch compatibility, ethanol evaporation, preservative performance, pH control, degradation products, and stability in the final packaged configuration. No biosimilar pathway applies. Glycopyrronium tosylate is a small-molecule drug, not a biologic. FDA competition would proceed through an ANDA or, for a materially different product, a 505(b)(2) application rather than a biosimilar application. How strong is the patent estate for Qbrexza?US 8,618,160 is strongest against a product that copies the full finished-product architecture. Its principal strengths are:
Its weaknesses are equally specific:
The patent is therefore a targeted product patent, not a broad platform patent. What manufacturing and intellectual-property barriers affect generic launch?A generic wipe must satisfy both pharmaceutical and package-performance requirements. The main barriers are: Formulation and analytical testingThe applicant must control glycopyrronium assay, impurities, pH, ethanol content, buffer concentration, and degradation under accelerated conditions. The less-than-0.5% degradation threshold creates a direct design target for any product that may fall within claim 1. Pouch and substrate compatibilityLLDPE is claimed in dependent claim 2, but other pouch structures may still fall within claim 1 if they are leakage-resistant. The pouch must limit solvent loss and prevent migration or interaction between the formulation and package. Product-specific bioequivalenceFor a topical wipe, FDA may evaluate drug release, product performance, dose delivery, active distribution, and local exposure. A liquid topical product, cream, gel, or pump spray may not qualify as an ANDA equivalent to an individually packaged cloth. Manufacturing know-howThe patent claims do not capture every manufacturing step. Separate trade secrets or patents may cover impregnation, sealing, pouch formation, sterilization or microbial control, drying control, and in-process testing. Those barriers can delay entry even when a design-around is available. What patent litigation and settlement issues matter?A Paragraph IV dispute would likely focus on four questions:
A settlement could provide a licensed launch date before patent expiry, an authorized-generic arrangement, or restrictions on formulation and manufacturing. A settlement date alone would not establish claim validity or infringement. Any current settlement or litigation position must be checked against PACER, FDA Orange Book updates, and USPTO records. How does US 8,618,160 compare with alternative hyperhidrosis products?
Key Takeaways
FAQsCan a glycopyrrolate gel infringe US Patent 8,618,160?A gel would generally avoid the individually packaged wipe limitation unless it is delivered on a claimed wipe. It could still implicate other patents in the broader glycopyrrolate or Qbrexza estate. Does using glycopyrronium bromide instead of glycopyrronium tosylate avoid the patent?Not necessarily. Claim 1 uses the broader phrase "glycopyrrolate compound." A different salt may remain within the claim if all other limitations are satisfied. Can a generic use a foil pouch instead of an LLDPE-lined pouch?Potentially. Claim 2 specifically requires an LLDPE inner lining, but claim 1 requires only a leakage-resistant pouch. A foil pouch could avoid claim 2 while still raising claim 1 issues. Does a pH of 5.0 avoid the patent?It may provide a design-around position, but the answer depends on how "about 4.5" is construed and whether the formulation meets the other limitations. Is a compounded glycopyrrolate wipe automatically an equivalent generic to Qbrexza?No. Compounded status does not establish FDA therapeutic equivalence, ANDA substitutability, or freedom from patent infringement. References
More… ↓ |
Drugs Protected by US Patent 8,618,160
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,618,160
| PCT Information | |||
| PCT Filed | October 17, 2008 | PCT Application Number: | PCT/US2008/011907 |
| PCT Publication Date: | April 23, 2009 | PCT Publication Number: | WO2009/051818 |
International Family Members for US Patent 8,618,160
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008314628 | ⤷ Start Trial | |||
| Australia | 2014203072 | ⤷ Start Trial | |||
| Canada | 2702830 | ⤷ Start Trial | |||
| European Patent Office | 2200550 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
